ACADIA Pharmaceuticals Inc. (ACAD) Earnings Call Transcripts
ACADIA Pharmaceuticals Inc.'s Latest Earnings Call - Q3 FY2026
In Q3 2026, AcadeMedia AB reported solid growth with revenues of SEK 19.8 billion, reflecting a year-on-year increase of 6.6%. The adjusted EBITA margin improved to 8.2%, up from 7.7% in the prior year, translating to an EBITA of SEK 438 million. Management maintained a positive outlook, emphasizing ongoing international expansion and a strong acquisition pipeline, although they flagged potential cost impacts from upcoming regulatory changes in Sweden.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | SEK 19.8 billion (beat) |
| Adjusted EBITA | SEK 438 million (beat) |
| Adjusted EBITA Margin | 8.2% (beat) |
| Free Cash Flow | SEK 1.444 million (beat) |
| Net Debt | SEK 508 million (negative) |
| Organic Growth | 5.6% (inline) |
Guidance from management
Management expects to continue growing in existing markets and is preparing for the legislative changes in 2027, estimating a one-off cost of SEK 25 million. They remain optimistic about maintaining profitability despite potential pressures.
What management said
We have done an uplift in margin in several of the countries and not the least in Germany. And we separate the operations in the Preschool German operation and the School operation. In school, mostly of the acquisitions we make are margin positive to the segment. And we also see potentially good integration improvements within 1, 2 years for these acquisitions. For the Preschool, there has been a significant part of ...
We expect that the absolute majority or absolute significant part of that amount will be made as investments in system, so that will be activated and will be depreciated over a couple of years or a number of years. So you won't have any single quarter where we have any substantial effect.
What analysts pressed on
Analysts expressed concerns regarding the sustainability of the improved margins in the Upper Secondary School segment and the potential impact of legislative changes on operational costs. There were also questions about the temporary nature of cost reductions in Norwegian operations.
Main topics on the call
- Revenue Growth — AcadeMedia achieved a revenue increase of 6.6% year-on-year, driven by strong performance in the Preschool and international segments. CEO Marcus Strömberg noted, "We continue to grow in a good way and also the financial...
- Acquisitions Strategy — The company announced five international acquisitions and one in Sweden, aiming for 50% of operations outside Swedish schools. Strömberg stated, "AcadeMedia is a strong company when it comes to acquisitions," highlightin...
- Legislative Impact — Management discussed upcoming legislation that will require independent educational providers to adhere to new transparency rules, estimating a one-off cost of SEK 25 million. CFO Petter Sylvan mentioned, "The ongoing im...
- Segment Performance — The Adult Education segment reported strong results with a 6.7% revenue increase, driven by higher vocational education demand. Sylvan noted, "Adult Education continues to report strong results driven by increased volume...
Read the full ACADIA Pharmaceuticals Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (ACAD) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 102 calls on record spanning January 14, 2020 to May 12, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 102 ACADIA Pharmaceuticals Inc. earnings call transcripts on record, spanning January 14, 2020 to May 12, 2026. Based on this history, ACADIA Pharmaceuticals Inc. reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ACAD
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 102
- First call
- January 14, 2020
- Most recent
- May 12, 2026
- Reporting cadence
- quarterly